Comparison of brain metabolic activity patterns induced by ketamine, MK- 801 and amphetamine in rats: Support for NMDA receptor involvement in responses to subanesthetic dose of ketamine

Brain Research

Volumn 843, Issue 1-2, 1999, Pages 171-183

  Duncan, Gary E ^a   Miyamoto, Seiya ^a   Leipzig, Jeremy N ^a   Lieberman, Jeffery A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Animal model; Hippocampus; Ketamine; Limbic system; MK 801; NMDA; Prefrontal cortex; Schizophrenia

Indexed keywords

AMPHETAMINE; DEOXYGLUCOSE; DIZOCILPINE; DOPAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN; BRAIN METABOLISM; CONTROLLED STUDY; DOPAMINE RELEASE; HIPPOCAMPUS; LIMBIC SYSTEM; MALE; MOTOR ACTIVITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; BRAIN; CARBON RADIOISOTOPES; DEOXYGLUCOSE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; ORGAN SPECIFICITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; REFERENCE VALUES; TISSUE DISTRIBUTION;

EID: 0032864258     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01776-X     Document Type: Article

References (76)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18:1998;5545-5554.
2. Adler C.M., Goldberg T.E., Malhotra A.K., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol. Psychiatry. 43:1998;811-816.
3. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Compr. Psychiatry. 2:1961;269-280.
4. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201.
5. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271:1994;787-794.
6. Bell D. Comparison of amphetamine psychosis and schizophrenia. Am. J. Psychiatry. 111:1965;701-707.
7. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry. 154:1997;805-811.
8. Bristow L.J., Hutson P.H., Thorn L., Tricklebank M.D. The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J Pharmacol. 108:1993;1156-1163.
9. Bubser M., Tzschentke T., Hauber W. Behavioural and neurochemical interactions of the AMPA antagonist GYKI Y1-52466 and the non-competitive NMDA antagonist dizocilpine in rats. J. Neural Transm. 101:1995;115-126.
10. Cohen M.L., Chan S.L., Bhargave H.N., Trevor A.J. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem. Pharmacol. 23:1974;1647-1652.
11. Coppel D.L., Bovill J.G., Dundee J.W. The taming of ketamine. Anesthesia. 28:1973;293-296.
12. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
13. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry. 3:1996;241-253.
14. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265:1993;1001-1010.
15. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
16. Deutsch S.I., Mastropaolo J., Schwartx B.L., Rosse R., Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia. Clin. Neuropharmacol. 12:1989;1-13.
17. Domino E.F., Chodoff P., Corssen G. Pharmacological effects of CI-581, a new dissociative anesthetic in man. Clin. Pharmacol. Ther. 6:1965;279-291.
18. Duncan G.E., Johnson K.B., Breese G.R.T. Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J. Neurosci. 13:1993;3932-3943.
19. Duncan G.E., Knapp D.J., Johnson K.B., Breese G.R. Functional classification of antidepressants based upon antagonism of swim stress-induced Fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 277:1996;1076-1089.
20. Duncan G.E., Leipzig J.N., Lieberman J.A. Effects of ketamine and MK-801 on regional 2-deoxyglucose uptake. Soc. Neurosci. Abstr. 291.5:1998;12.
21. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
22. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 787:1998;181-190.
23. Duncan G.E., Stumpf W.E. Brain activity patterns: assessment by high resolution autoradiographic imaging of radiolabeled 2-deoxyglucose and glucose uptake. Prog. Neurobiol. 37:1991;365-382.
24. Freeman A.S., Bunney B.S. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol. 104:1984;287-293.
25. French E.D. Effects of phencyclidine on ventral tegmental A10 dopamine neurons in the rat. Neuropharmacology. 25:1986;241-248.
26. French E.D., Ceci A. Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci. Lett. 119:1990;159-162.
27. French E.D., Ferkany J., Abreu M., Levenson S. Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology. 30:1991;1039-1046.
28. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16:1996;2034-2043.
29. Hammer R.P., Herkenham M. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J. Comp. Neurol. 220:1983;396-404.
30. Hauber W., Andersen R. The non-NMA glutamate receptor antagonist GYKI Y1-52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;486-490.
31. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. 89:1992;1-10.
32. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimaura H., Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex, an in vivo microdialysis study. Brain Res. 633:1994;337-342.
33. Imperato A., Scrocco M.G., Bacchi S., Angelucci L. NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol. 187:1990;555-556.
34. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
35. Keefe K.A., Zigmond M.J., Abercrombie E.D. In vivo regulation of extracellular dopamine in the neostriatum influence of impulse activity and local excitatory amino acid release. J. Neural Transm. 91:1993;223-240.
36. Kramer J.C., Gischman V., Littlefield D. Amphetamine abuse - pattern and effects of high doses taken intravenously. J. Am. Med. Assoc. 201:1967;89-93.
37. Krystal J.H., Karper L.P., Bennett A., D'Souza D.C., Abi-Dargham A., Morrissey K., Abi-Saab D., Bremner J.D., Bowers M.B.J., Suckow R.F., Stetson P., Heninger G.R., Charney D.S. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology. 135:1998;213-229.
38. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B.J., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
39. Kurumaji A., Nehls D.G., Park C.K., McCulloch J. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 496:1989;268-284.
40. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872.
41. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
42. Lieberman J.A., Kane J.M., Alvir J.A.J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
43. Loscher W., Honack D. The behavioral effects of MK-801 in rats - involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 214:1992;199-208.
44. Luby E.D., Cohen B.D., Rosenbaum G., Gottilieb J.S., Kelley R. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psychiatry. 81:1959;363-369.
45. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668.
46. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
47. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition - the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
48. Martin P., Svensson A., Carlsson A., Carlsson M.L. On the roles of dopamine D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801. J. Neural Transm.: Gen. Sect. 95:1994;113-121.
49. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia - a review. Schizophr. Bull. 2:1976;19-76.
50. Moghaddam B., Adams B., Verman A., Daly D. Activation of glutamatergic neurotransmission by ketamine - a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
51. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotrophic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
52. Murase S., Mathe J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential action on firing pattern related to anatomical localization. J. Neural Transm. 91:1993;13-25.
53. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
54. Orzi F., Dow-Edwards D., Jehle J., Kennedy C., Sokoloff L. Comparative effects of acute and chronic administration of amphetamine on local cerebral glucose utilization in the conscious rat. J. Cereb. Blood Flow Metab. 3:1983;154-160.
55. Ouagazzal A., Nieoullon A., Amalric M. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology. 1:1993;427-434.
56. N. Oye, O. Hustveit, P.J. Moberg, O. Pausen, L.A. Skoglund, The chiral forms of ketamine on probes for NMDA receptor function in humans, in: T. Kameyama, T. Nebeshima, E.F. Domino (Eds.), NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior, NPP Books, Ann Arbor, MI, 1991, pp. 381-389.
57. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 1997.
58. Porrino L.J., Lucignani G., Dow-Edwards D., Sokoloff L. Correlation of dose-dependent effects of acute amphetamine administration on behavior and local cerebral metabolism in rats. Brain Res. 307:1984;311-320.
59. Rao T.S., Kim H.S., Lehman J., Martin L.L., Wood P. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci. 45:1989;1067-1072.
60. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine relase effects of competitive NMDA or 5-HT2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
61. Sharp J.W., Petersen D.L., Langford M.T. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp 70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 687:1995;114-124.
62. Smith D.J., Azzaro A.J., Zaldivar S.B., Palmer S., Lee H.S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology. 120:1981;391-396.
63. Smith D.J., Pekoe G.M., Martin L.L., Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci. 26:1980;789-795.
64. Snyder S.H., Banerjee S.P., Yamamura H.I., Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science. 184:1974;1243-1253.
65. Steinfels G.F., Tam S.W., Cook L. Electrophysiological effects of selective sigma-receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons. Neuropsychopharmacology. 2:1989;201-208.
66. Swerdlow N.R., Bakshi V.P., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 279:1996;1290-1299.
67. Swerdlow N.R., Keith V.A., Braff D.L., Geyer M.A. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exp. Ther. 256:1991;530-536.
68. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats modulation by dopamine. J. Neurosci. 16:1996;373-379.
69. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur. Neuropsychopharmacol. 7:1997;25-38.
70. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J., Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 7:1997;9-24.
71. Wang R.Y., Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85.
72. Wechsler L.R., Savaki H.E., Sokoloff L. Effects of D- and L-amphetamine on local cerebral glucose utilization in the conscious rat. J. Neurochem. 32:1979;15-22.
73. Wedzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622:1993;325-329.
74. Willins D.L., Narayanan S., Wallace L.J., Uretsky N.J. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol. Biochem. Behav. 46:1993;881-887.
75. Wolf M.E., White F.J., Hu X.T. Behavioral sensitization to MK-801 (dizocilpine) - neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav. Pharmacol. 4:1993;429-442.
76. Yenari M.A., Bell T.E., Kotake A.N., Powell M., Steinberg G.K. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin. Neuropharmacol. 21:1998;28-34.